Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

Title
Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
Authors
Keywords
Regorafenib, Avelumab, Biliary tract cancer, Immunotherapy, Cholangiocarcinoma
Journal
EUROPEAN JOURNAL OF CANCER
Volume 162, Issue -, Pages 161-169
Publisher
Elsevier BV
Online
2022-01-06
DOI
10.1016/j.ejca.2021.11.012

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation